TY - JOUR
T1 - Programmed death-ligand 1 immunohistochemistry in lung cancer
T2 - In what state is this art?
AU - Kerr, Keith M.
AU - Tsao, Ming Sound
AU - Nicholson, Andrew G.
AU - Yatabe, Yasushi
AU - Wistuba, Ignacio I.
AU - Hirsch, Fred R.
N1 - Funding Information:
International Association for the Study of Lung Cancer (IASLC) Pathology Committee members: Chair —AG Nicholson, Royal Brompton Hospital, London, United Kingdom. Biomarker subgroup —KM Kerr (IASLC Board Liaison), Aberdeen University Medical School, Aberdeen, United Kingdom; Y Yatabe, Aichi Cancer Centre, Nagoya, Japan; MS Tsao, Princess Margaret Hospital, Toronto, Canada; II Wistuba, MD Andersen cancer Center, Houston, Texas; and FR Hirsch (CEO IASLC), University of Colorado Cancer Center, Denver, Colorado. Members —MB Beasley, Mount Sinai Hospital, New York; E Brambilla, CHU Albert Michallon, Grenoble, France; J Botling, Uppsala University, Sweden; LR Chirieac, Brigham and Women’s Hospital, Boston, Massachusetts; S Dacic, University of Pittsburg Medical Center, Pennsylvania; K Geisinger, The University of Mississippi Medical Center, Jackson, Mississippi; G Pelosi, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; Y Ishikawa, Japanese Foundation for Cancer Research, Tokyo, Japan; N Lertprasertsook, Chiang Mai University, Chiang Mai, Thailand; A Moreira, Memorial Sloan Kettering Cancer Center, New York, New York; M Noguchi, University of Tsukuba, Tsukuba, Japan; I Petersen, Jena University Hospital, Jena, Germany; E Thunnissen, VUMC, Amsterdam, Netherlands; KF To, Chinese University of Hong Kong, Hong Kong; and WD Travis, Memorial Sloan Kettering Cancer Center, New York, New York.
Publisher Copyright:
© 2015 by the International Association for the Study of Lung Cancer.
PY - 2015/7/4
Y1 - 2015/7/4
N2 - Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show promising clinical results. Anti-PD-L1 immunohistochemistry (IHC) may be a biomarker to select patients more likely to respond to these treatments. However, the development of at least four different therapeutics, each with a different anti-PD-L1 IHC assay, has raised concerns among pathologists and oncologists alike. This article reviews existing data on the IHC biomarker aspects of studies using these drugs in non-small-cell lung cancer (NSCLC) and considers the challenges ahead, should these drug/IHC assay combinations reach routine practice. For each the known biomarker assays in development, there is a different monoclonal IHC antibody clone, produced by one of two diagnostics companies. Each test requires proprietary staining platforms and uses different definitions of a "positive" test for PD-L1 expression, on tumor cells and, in one test, also on tumor infiltrating immune cells. There are still considerable gaps in our knowledge of the technical aspects of these tests, and of the biological implications and associations of PD-L1 expression in NSCLC, considering heterogeneity of expression, dynamic changes in expression, and prognostic implications among other factors. The International Association for the Study of Lung Cancer Pathology Committee raises the prospect of trying not only to harmonize and standardize testing for PD-L1 by IHC, at least at a technical level, but also, ideally, as a predictive marker, to facilitate availability of this test and a promising treatment for patients with NSCLC.
AB - Therapeutic antibodies to programmed death receptor 1 (PD-1) and its ligand PD-L1 show promising clinical results. Anti-PD-L1 immunohistochemistry (IHC) may be a biomarker to select patients more likely to respond to these treatments. However, the development of at least four different therapeutics, each with a different anti-PD-L1 IHC assay, has raised concerns among pathologists and oncologists alike. This article reviews existing data on the IHC biomarker aspects of studies using these drugs in non-small-cell lung cancer (NSCLC) and considers the challenges ahead, should these drug/IHC assay combinations reach routine practice. For each the known biomarker assays in development, there is a different monoclonal IHC antibody clone, produced by one of two diagnostics companies. Each test requires proprietary staining platforms and uses different definitions of a "positive" test for PD-L1 expression, on tumor cells and, in one test, also on tumor infiltrating immune cells. There are still considerable gaps in our knowledge of the technical aspects of these tests, and of the biological implications and associations of PD-L1 expression in NSCLC, considering heterogeneity of expression, dynamic changes in expression, and prognostic implications among other factors. The International Association for the Study of Lung Cancer Pathology Committee raises the prospect of trying not only to harmonize and standardize testing for PD-L1 by IHC, at least at a technical level, but also, ideally, as a predictive marker, to facilitate availability of this test and a promising treatment for patients with NSCLC.
KW - Biomarker assay
KW - Immune check-point inhibitors
KW - Immunohistochemistry
KW - PD-1
KW - PD-L1
UR - http://www.scopus.com/inward/record.url?scp=84942867600&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942867600&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000526
DO - 10.1097/JTO.0000000000000526
M3 - Review article
C2 - 26134220
AN - SCOPUS:84942867600
SN - 1556-0864
VL - 10
SP - 985
EP - 989
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 7
ER -